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1. Introduction 
Cannabinoids are drugs that are either derived from cannabis or that induce similar 
behavioural and physiological effects to cannabis. They fall into three classes: those that are 
produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); 
those that are produced within the body, termed endocannabinoids (endogenous 
cannabinoids); and those that are produced synthetically to mimic the pharmacology of 
naturally occurring cannabinoids. 
Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, 
and methadone stand in relation to opium. While opium and opioids are used and abused 
recreationally, opioids have long been at the forefront of first line analgesia for acute and 
chronic pain indications. Similarly, while cannabis and synthetic analogues are drugs of 
abuse, cannabinoids also have beneficial therapeutic effects. While the therapeutic effects of 
cannabinoids do not yet approach those of opioids, there has been extensive pharmaceutical 
research into the use of cannabinoids for the treatment of pain. In contrast with opioids, 
however, there is mounting evidence that cannabinoids may be more efficacious in the 
treatment of chronic pain conditions, such as neuropathies, rather than acute pain. 
2. Cannabinoid pharmacology 
2.1 A brief history 
Phytocannabinoids are derived from the Cannabis species, primarily Cannabis sativa which 
originated in China and Central and South Asia. Two other species are known; C. indica and 
C. Ruderalis, and possibly a third; C. afghanica. Of these, C. sativa is the largest and most 
diverse genus (Clarke et al., 2002). Cannabis was probably first used as a medicinal herb in 
India around 800BC, and in Persia and Tibet by 500BC, purportedly as an anaesthetic during 
surgery, while the therapeutic properties of cannabis were first recorded in China as early as 
200 AD. It wasn’t until the nineteenth century, however, that the Irish doctor William 
O’Shaughnessy began the scientific investigation of the chemical properties of cannabis 
(Frankhauser, 2002).  
By 1900 various pharmaceutical companies in Europe were promoting cannabis based 
products for the treatment of migraine, menstrual cramps, whooping cough, asthma, and as 
a sedative and soporific. During the twentieth century, however, cannabis lost favor as a 
medicine due to combination of the development of better drugs, the instability of cannabis 
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drug formulations, unfavorable economics, and legal restrictions on its availability 
(Frankhauser, 2002). Today, cannabis and cannabinoids are once again the subject of serious 
pharmaceutical development. More targeted drug formulations, a greater understanding of 
the evidence base for cannabinoid efficacy and safety for particular conditions, and the 
development of wholly new ways of manipulating the endocannabinoid system have lead 
to a resurgence of research. 
Following the initiation of the scientific study of cannabinoid chemistry in 1838 by 
O’Shaughnessy (Di Marzo, 2006a), the first purified cannabinoid, named cannabinol, was  
isolated in 1899, and by 1932, its structure had been partially described. In 1964 Raphael 
Mechoulam, at Hebrew University in Israel, described the structure of the principle 
pharmacologically active component of cannabis, delta-9-tetrahydrocannabinol (THC) 
(Mechoulam et al., 1965). Following this critical discovery, the study of the pharmacological 
effects of cannabis and cannabinoids accelerated from 1970 through to the 1990s. This period 
of cannabinoid pharmacology clarified the behavioural and physiological effects of cannabis 
and classical cannabinoids, in particular THC. 
It had already been discovered that opium derived opioids interact with an endogenous 
receptor system, mimicking the actions of endogenous opioids. It was hypothesised that a 
similar receptor binding system might underlie the effects of cannabinoids, and in 1988, 
Devane and colleagues (Devane et al., 1988) published an article describing and 
characterising binding sites for THC. This rapidly led to the discovery of a specific 
cannabinoid receptor, subsequently termed cannabinoid receptor I, or CB1, in 1990 
(Herkenham et al., 1990a). A seminal study by Herkenham and colleagues (Herkenham et al., 
1990a) used autoradiographical binding to describe the distribution of CB1 receptors 
throughout the rat brain. Soon afterward, a similar distribution of CB1 receptors was 
described for the human brain by Glass and colleagues (Glass et al., 1997). The results of 
these studies helped explain many of the psychoactive effects of cannabinoids that had been 
previously characterized. 
The discovery of the CB1 receptor gave impetus to the search for endogenous cannabinoids 
for which CB1 would be the natural target. The first endogenous ligand discovered and 
characterised for this receptor was a lipid, arachidonoylethanolamide, discovered in 1992, 
and given the name anandamide after the Sanskrit word for bliss, ananda (Devane et al., 
1992). Anandamide is not stored in vesicles like classical neurotransmitters, and is instead 
synthesized in neurons on demand primarily via a two step reaction, catalysed by N-
acyltransferase and a member of the phospholipase D family, N-
acylphosphatidylethanolamine (Okamoto et al., 2007). It is a highly lipophilic derivative of 
arachidonic acid and readily diffuses across the plasma membrane upon synthesis, 
activating CB1 receptors before rapid enzymatic hydrolysis by fatty acid amide hydrolase 
(FAAH) (Cravatt et al., 1996). This makes anandamide ideally adapted for signaling 
pathways that require a rapid and local response, such as the regulation of neuronal 
excitability in the brain, or the modulation of vascular tone. A second endocannabinoid, 2-
arachodonalglycerol (2-AG), was discovered in 1995 (Mechoulam et al., 1995). Like 
anandamide, synthesis and degradation of 2-AG is enzymatically regulated, in this instance 
primarily by diacylglycerol lipase ┙ and ┚, and monoglyceride lipase (Dinh et al., 2002), 
respectively. More recently there have been at least four additional endocannabinoids 
suggested: 2-arachidonyl-glycerolether (noladin, 2-AGE), O-arachidonyl-ethanolamine 
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(virohdamine), N-arachidonoyl-dopamine (NADA) (Pacher et al., 2006), and the sleep 
inducing oleic acid derivative oleamide (Lees et al., 2004), although these have not been as 
extensively characterized as anandamide and 2-AG. 
A second cannabinoid receptor, cannabinoid receptor II (CB2), was discovered in 1992 
(Munro et al., 1993). Unlike CB1, CB2 appeared to be abundant in immune cells of the spleen 
(lymphocytes) and tonsils but not in the brain (Galiegue, 1995). This finding helped explain 
another of the pharmacological effects of cannabis; suppression of the immune system.  
2.2 Cannabinoid receptors 
CB1 occurs in deuterostome invertebrate animals as well as in vertebrates, which suggests 
that the endocannabinoid system developed early in evolutionary history and is therefore 
likely to be fundamental to a variety of basic physiological processes (Elphick et al., 2001). 
These include processes that are mainly involved with both the central and peripheral 
nervous systems, though CB1 is most densely expressed in the central nervous system 
(CNS). In addition to the psychoactive effects of CB1 activation in the brain, CB1 receptors 
have a number of functions in other organ systems. CB1 is co-expressed with CB2 in many 
immune cells, including monocytes and microglia. Some researchers have suggested that 
CB1 may be constitutively expressed in immune cells, and respond to initial injury signals, 
and that a second receptor, CB2,  is induced during inflammation or immune functions 
(Cabral et al., 2005). CB1 receptors are in fact expressed in a great many tissues throughout 
the body, including in the eye (where they help regulate intraocular pressure), the placenta, 
gonads and reproductive system, skin, and in nerves terminating in the gut wall (Izzo et al., 
2001; Park et al., 2003; Njie et al., 2006). There are also CB1 receptors in cardiac muscle, blood 
vessels, and on peripheral nerves of the cardiovascular system.  
CB2 was characterized shortly after CB1 (Munro et al., 1993). CB2 receptors are found at the 
highest densities in immune cells, and as such, spleen and tonsil homogenates show very 
high levels of CB2 protein. For this reason, CB2 has come to be referred to as the 
cannabinoid immune receptor, contrasting with CB1 as the cannabinoid central nervous 
system receptor. There are exceptions to this however: as noted CB1 is found in a variety of 
tissues including immune cells, and CB2 has been found to be important in the proliferation 
and differentiation of immature neurons. Because CB2 is located for the most part in 
peripheral tissues and in immune cells in particular, CB2 represents an attractive target for 
the immunomodulatory and anti-inflammatory effects of cannabinoids, but without the 
psychoactive effects caused by CB1 activation.  
Although CB2 expression is well characterized in the immune system (Galiegue et al., 1995), 
the expression of the CB2 receptor in the brain is still an area of controversy. It is known 
now that CB2 are definitely expressed in microglia, which are resident immune cells in the 
CNS (Cabral et al., 2005). CB2 has been detected in microglia in neuritic plaques in brains 
taken from patients that have died with Alzheimer’s disease (Benito et al., 2003). More 
controversially, CB2 receptors have also been reported on neurons of rodents and mustelids 
(Van Sickle et al., 2005; Gong et al., 2006; Onaivi et al., 2006). 
CB1 and CB2 are G protein coupled receptors (GPCRs), linked to inhibitory Gi proteins. 
Activation of these receptors inhibits the accumulation of the messenger molecule cyclic 
adenosine monophosphate (cAMP) in cells, via inhibition of adenylyl cyclase (Scotter et al., 
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2006). GPCRs are extremely abundant and variable, but share the same basic structure; 
which is an extracellular N terminus, an intracellular C terminus, seven hydrophobic trans-
plasma membrane helical domains, three extracellular loops, and three intracellular loops. 
Cellular signalling pathways for CB1 are well studied; less so for CB2. Stimulation of the 
CB1 receptor inhibits the influx of Ca2+ into cells by way of a variety of voltage sensitive 
Ca2+ channels (VSCCs). In the brain, depolarization of postsynaptic neurons can cause a 
release of endocannabinoids that act as reverse neurotransmitters to presynaptic CB1 
receptors, reducing neurotransmitter release from presynaptic neurons. As CB1 receptors 
are present on both excitatory and inhibitory neurons, its activation can have diverse and 
often opposing effects in the central nervous system. CB1 is also coupled to G protein-
coupled inwardly rectifying potassium channels (GIRKs), and this tends to hyperpolarize 
presynaptic neuron terminals, and contributes to the reduction in excitation/inhibition of 
post-synaptic neurons. Inhibition of VSCCs has also been implicated as a key mechanism by 
which vascular CB1 receptors mediate vasodilation. 
It is important to remember that much of the research that has been done on cannabinoid 
receptors has been done on those found in rodents, particularly rats. The amino acid 
sequence for CB1 is very similar in rats and humans, with 97% sequence identity between 
the two species (Gerard et al., 1991). Although CB1 is highly conserved between species, the 
same cannot be said for CB2. CB2 has diverged a great deal more between species than CB1, 
with only 81% sequence identity between the rat and human receptors (Griffin et al., 2000). 
Modeling the receptors has shown that there is some 87% identity between the rat and 
human receptors in the transmembrane regions, which are critical for drug binding. 
Therefore, although CB1 rat models are often (but not always) good predictors of how a 
drug will perform for human CB1 receptors, this is not so frequently the case for CB2. Drugs 
that show promising selectivity for CB2 that have only been tested in rodents should 
therefore be treated with caution when extrapolating possible effects in humans.  
While CB1 and CB2 are two undisputed and well characterised members of the cannabinoid 
receptor family by which cannabinoids exert their effects, there is evidence of cannabinoid 
binding to additional targets. Some effects by cannabinoids in experiments do not appear to 
be mediated by either CB1 or CB2. In particular, the endocannabinoid anandamide may act 
on a variety of targets including a number of orphaned GPCRs (such GPR55, GPR112) T-
type Ca2+ channels, Na2+ channels, Transient Receptor Potential Vanilloid type 1 (TRPV1) 
channels, 7-nicotinic acetylcholine receptors, and background and voltage-gated K+ 
channels (van der Stelt et al., 2005).  
Although cannabinoid analgesia has been reasonably well studied in humans (Pertwee, 
2001; Burns et al., 2006; Huskey, 2006; Manzanares et al., 2006) the exact contributions of the 
cannabinoid receptors is still under investigation. Many preclinical studies have shown that 
cannabinoids produce analgesia by acting in both the central and peripheral nervous system 
(Pertwee, 2001), via CB1 receptors in the brain, but also by both CB1 and CB2 receptors in 
the spinal cord and periphery (Agarwal et al., 2007).  
2.3 Cannabinoids 
Cannabinoids tend to fall into five major structural classes: The classical cannabinoids 
(including phytocannabinoids), bicyclic and tricyclic analogues, endocannabinoids, 
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aminoalkylindoles, and diarylpyrazoles. While classical cannabinoids are based on the 
structure of phytocannabinoids, the other four classes of ligand are not, and tend to have a 
non-classical structure. 
The first classical cannabinoids were the phytocannabinoids purified from the cannabis 
plant, C.sativa. At least 483 different natural chemicals have been extracted and purifed from 
cannabis and of these, phytocannabinoids are exclusively found in cannabis plants. At the 
time of writing, 66 distinct phytocannabinoids have been isolated and purified from C.sativa. 
These include THC and cannabidiol, which have been extensively studied for their 
medicinal qualities. Dronabinol is the name given to the synthetically produced (-)-trans-
isomer of THC (which is also naturally occurring), while nabilone, also a classical 
cannabinoid, is a synthetically produced potent analogue of THC. Both dronabinol and 
nabilone are currently licensed medications, and are discussed later.  
With the characterisation of specific cannabinoid receptors, it was possible to develop 
synthetic compounds tailored directly to the cannabinoid receptors, which differed from the 
classical cannabinoid structure. Bicyclic and tricyclic synthetic cannabinoids of the non-
classical type make up the second group of cannabinoid ligands. Chief among agonists of 
this group, CP55,940 was developed by Pfizer in 1974, and is a bicyclic cannabinoid, without 
the middle dihydropyran ring of the classical tricyclic cannabinoids. These were altered 
further by the substitution of additional hydroxyl groups for added capability to form 
hydrogen bonds. CP55,940 is considerably more potent as an agonist at both cannabinoid 
receptors compared with THC. As a result, the psychoactive effects of CP55,940 are far more 
intense than those caused by THC (which is a relatively weak cannabinoid receptor agonist) 
and therefore CP55,940 has not been suitable for clinical use. Unlike dronabinol and 
nabilone, CP55,940 and other drugs like it have never been marketed because they are 
extremely psychoactive (i.e., cause profound effects on the central nervous system).  
Levonantradol is a tricyclic cannabinoid that was produced by Pfizer, and differs from THC 
not only in that it has additional hydrogen binding sites, but also in that it has an aromatic 
group attached to the alkyl tail. Levonantradol is considerably more potent than THC, and 
unlike CP55,940, was used in clinical tests. Levonantradol was found to provide 
considerable pain relief for patients after operations, but had more intense side effects than 
THC (Jain et al., 1981). Another potent tricyclic THC analogue that has been used 
extensively in studying the endocannabinoid system is HU-210. With a long duration of 
action, and exhibiting 100-800 times more potency than THC, it is unsuitable for human use. 
Like other potent synthetic cannabinoids HU-210 has a high degree of oxygen substitution 
compared with phytocannabinoids. Ajulemic acid is compound that is related to HU-210, 
and is a synthetic derivative of the active metabolite of THC, 11-carboxy-THC. Ajulemic acid 
is similar in structure to HU-210, but has a carboxylate substituted for the methyl hydroxyl 
substituent at position 9. Ajulemic acid has been administered to humans in clinical tests, 
and has been found to have promise for the control of neuropathic pain. 
Synthetic cannabinoids were initially developed based on the classical cannabinoid 
structural template (Di Marzo, 2006b). Phytocannabinoids are highly lipophilic and show 
extremely high levels of non-specific binding in radio-ligand binding experiments. Highly 
potent synthetic analogues of THC are often more polar than phytocannabinoids, and able 
to form more hydrogen bonds. Because THC and its derivatives tend to be highly lipophilic, 
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it accumulates in cell membranes when it is applied to sectioned or homogenised tissues. 
For many years, this made it difficult to identify and characterise the specific binding sites 
for cannabinoids, which hindered study of the endocannabinoid system. Identification of 
cannabinoid receptors and their distribution in the body has been greatly facilitated by the 
discovery of high affinity compounds such as CP 55,940. Radio-labeled CP 55,940 was the 
compound used by Devane and colleagues (Devane et al., 1988) in the breakthrough work 
that lead to the characterisation CB1, and by  Herkenham and colleagues to describe the 
distribution of CB1 in the rat brain (Herkenham et al., 1990b).  
A third group of cannabinoids consists of endocannabinoids, which were first identified 
soon after the characterisation of cannabinoid receptors (Di Marzo, 2006b). The prototypical 
endocannabinoid is anandamide and has been extensively studied for both its biochemistry 
and pharmacology. Anandamide consists of a long hydrophobic alkyl tail, and an 
ethanolamide head group. The endocannabinoid 2-AG differs from anandamide by the 
addition of a second hydroxyl at the headgroup, and an ester group replacing the amide. 
Anandamide appears to have several-fold greater potency than 2-AG, though there is 
enormous variation in published results. 
A fourth category of cannabinoids, bearing little structural similarity to either classical 
cannabinoids or endocannabinoids are aminoalkylindoles, the most commonly used of 
which is WIN55,212-2, which is a potent agonist at both CB1 and CB2 receptors, but shows 
some degree of selectivity for CB2. JWH-133 is another potent indole that is part of a family 
of compounds named after their discoverer, JW Huffman, and shows a high degree of 
selectivity (200-fold) for CB2 (Huffman, 2005).  
Non-classical ligand development also included, for the first time, receptor subtype selective 
antagonists. Developed by Sanofi-Recherche in the 1990s, SR141716A (later SR141716) and 
SR144528 are highly selective antagonists against CB1 and CB2, respectively, and are 
members of the fifth main category of cannabinoids, the diarylpyrazoles  (Rinaldi-Carmona 
et al., 1994). By virtue of selectively excluding the actions of one of the cannabinoid 
receptors, these two compounds have been instrumental in critical research that has 
furthered our understanding of cannabinoid pharmacology. Indeed these agonists were 
used to provide definitive evidence that CP 55,940 causes its effects through the same 
biochemical pathways as THC, in experiments that show that its psychoactive effects are 
completely blocked by the CB1 receptor antagonist SR141716 (Compton et al., 1992). 
Knowledge of receptor selectivity is important for the medicinal use of cannabinoids 
because CB1 and CB2 have distinct distributions and distinct physiological effects; CB1 is 
chiefly responsible for the psychoactive effects of cannabinoids and CB2 is mainly involved 
in the anti-inflammatory and immunomodulatory effects of cannabinoids. Development of 
subtype selective ligands will be discussed in a later chapter. 
3. Cannabis and cannabinoids in the clinic 
3.1 Cannabis 
Most of the higher quality evidence for the antinociceptive effects of cannabinoids in 
humans comes from studies using licensed cannabinoid drugs, rather than with medical 
cannabis. Very few clinical trial data for smoked cannabis exist, though there are some for 
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HIV-induced neuropathy (Abrams et al., 2007) and experimental pain (Hill et al., 1974; 
Wallace et al., 2007). It is also difficult to interpret case histories and patient or doctor 
testimonies, mostly because of the lack of placebo controls, but also because habitual 
cannabis users can develop tolerance to many of the effects of the drug. Moreover, the 
amount of active cannabinoids in any given cannabis cigarette is highly variable: THC 
content in raw cannabis often ranges between 1.5 and 3.7%; the size of the cannabis 
cigarettes can vary; and the amount of cigarette smoked at any one time can vary.  
3.2 Licensed formulations 
The cannabinoid drugs that were first approved for clinical use were synthetic analogues 
or stereoisomers of THC. These are the (-)-trans-isomer of THC, dronabinol (MarinolTM, 
Namisol®), and the more potent THC analogue, nabilone (CesametTM). Both dronabinol 
and nabilone are used clinically in several countries, especially in palliative care. This 
abstracts from the ability of cannabis to reduce nausea and vomiting after treatment with 
anti-cancer medicines (Machado Rocha et al., 2008). There is good evidence and 
justification for the continued use of cannabinoids in the treatment of nausea and 
vomiting in patients receiving chemotherapy, especially in those patients whose nausea 
and emesis does not respond to other treatments. In addition to anti-emetic action, they 
are also used as appetite stimulants in wasting conditions such as HIV/AIDS. Another 
THC analogue, levonantradol, has both anti-emetic and powerful analgesic properties. It 
was effective in the treatment of post surgical pain (Jain et al., 1981), and as an antiemetic 
in cancer patients (Cronin et al., 1981; Hutcheon et al., 1983; Stambaugh et al., 1984). 
However, adverse events were common, and sometimes severe and dose limiting (Cronin 
et al., 1981; Hutcheon et al., 1983), thus the drug was judged unacceptable and the 
programme was dropped (Dr K. Koe quoted in (Iversen, 2000)).  
Marinol is an oral form of dronabinol that is manufactured by Unimed Pharmaceuticals, and 
is available in the United States, Canada, and in some European countries. Marinol comes as 
capsules with the dronabinol dissolved in sesame seed oil. These are available in sizes of 2.5, 
5 and 10 mg. In an effort to improve the pharmacokinetic profile of orally administered 
dronabinol, Echo Pharmaceuticals in The Netherlands has developed Namisol, a 
preparation of dronabinol formulated with an emulsifier in oral tablets. The company is 
currently preparing phase II clinical trials of Namisol in neuropathic pain, multiple sclerosis 
and Alzheimer’s disease. Nabilone is marketed under the name Cesamet, which is a 
registered trademark of Valeant Pharmaceuticals International. Cesamet comes in the form 
of crystalline powder capsules, containing 1 mg nabilone, and is available in the UK, 
Canada, and in some European countries.  
A unique cannabinoid preparation that is currently in clinical use is GW Pharmaceutical’s 
cannabis-plant derived medicine, SativexTM (GW-1000). This is a natural preparation that 
standardises THC with cannabidiol in a fixed ratio (1:1.08) and is administered using 
sublingual sprays or tablets, and oromucosal or oropharyngeal sprays (Smith, 2004). 
Cannabidiol is thought to have a quite different mechanism of action to THC, and so Sativex 
is a more complex drug than the pure form of THC or THC analogues. In theory, 
cannabidiol should work in synergy with THC to increase some of its beneficial effects, and 
reduce some of its adverse effects. By using a whole plant extract, GW Pharmaceuticals hope 
to retain some of the putative properties of whole cannabis, as opposed to isolated THC, but 
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in concentrations that are below that which are thought to cause the major detrimental effects 
of cannabis. By combining THC and cannabidiol in a fixed ratio, and processing the whole 
plant extract such that concentrations are precisely specified, Sativex can be administered as a 
metered and recordable dose, unlike cannabis. Sativex has been approved for use in Canada as 
a treatment to help reduce pain and tremor in patients with multiple sclerosis, and has been 
approved for off label use in other countries. Similarly, Cannador® consists of capsules 
containing a standardized cannabis extract, with a 2:1 ratio of THC to cannabidiol. The 
cannabis has been grown in Switzerland and processed in Germany, organised by the Institute 
for Clinical Research (IKF) in Berlin. While Cannador has been used in clinical testing for a 
number of indications, it has not been licensed for therapeutic use. 
While many cannabinoid formulations are not specifically licensed for pain conditions, 
managing pain is a very useful side effect of cannabinoids used in palliative care in 
conditions such as HIV/AIDS and multiple sclerosis, and for the adverse effects of 
chemotherapy. HIV infection is a well known cause of periperheral neuropathies, while 
multiple sclerosis is a demyelinating neurodegenerative disorder that can also cause serious 
neuropathic path. Some chemotherapeutics can also cause neuropathies and chronic pain, 
for example paclitaxel (taxol), a frontline anticancer therapeutic.  
3.3 Pharmacokinetics  
When smoked, 10 to 25% of the THC content of cannabis leaf is absorbed into the 
bloodstream (Adams et al., 1996). Via the inhalation route, THC reaches peak levels much 
faster, and ultimately reaches higher peak plasma concentrations than via oral or even 
oromucosal administration of THC. In one study, smoking cannabis resulted in peak plasma 
concentrations of THC more than 10 times greater than an equivalent dose of THC given by 
oromucosal spray, and peak plasma concentrations were reached within 9 minutes, 
compared to 180 minutes (Robson, 2005). The high peak plasma concentrations of THC that 
are achieved very rapidly by smoking cannabis may help explain why some users claim that 
the medical benefits of smoked cannabis are greater than for other THC preparations 
(Medicines and Healthcare products Regulatory Agency, 2007). However, the “peak and 
trough” pharmacokinetics of smoked cannabis means that users experience significantly 
greater psychoactivity than when using Sativex, where gradual dose titration to steady state 
plasma concentrations is possible.  
Via the oral route, cannabinoids are absorbed much more slowly than via the inhalation 
route, yet tend to have a longer duration of action. Nabilone and dronabinol are both highly 
lipophilic compounds, with similar pharmacokinetic profiles when delivered orally. While 
nabilone and dronabinol have a similar time to onset of action (60 – 90 min and 30 – 60 min, 
respectively) and peak plasma concentration (2 hours and 2 - 4 hours, respectively), nabilone 
has a longer duration of action (8 - 12 hours versus 4 – 6 hours, respectively), allowing less 
frequent dosing. A typical dosing regimen for nabilone in the treatment of chemotherapy-
induced nausea and vomiting is 1-2 mg taken 1 to 3 hours prior to chemotherapy and 2 
times a day for up to 2 days afterward. For dronabinol, 5 mg may be given 1 to 3 hours 
before chemotherapy, and every 2 to 4 hours afterwards for a total of 4 to 6 doses each day. 
Because cannabinoids are highly lipophilic and pass easily through biological membranes, 
they can be administered using sublingual sprays or tablets, and oropharyngeal or 
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oromucosal sprays, as Sativex is. This avoids both first pass metabolism that occurs in oral 
administration, and the problems associated with smoking and pulmonary administration, 
while retaining rapid uptake into the blood stream and dispersal around the body and the 
nervous system that is characteristic of cannabis. 
Dronabinol (THC) is primarily metabolized by the cytochrome P450 (CYP450) 2C9 enzyme 
into 11-hydroxy-THC, and to a lesser degree by CYP3A4 into 7- or 8-hydroxy metabolites 
(Watanabe et al., 2007). The metabolite 11-hydroxy-THC is pharmacologically active, and 
polymorphisms of CYP2C9 have been shown to be related to differences in THC response 
profiles (Sachse-Seeboth et al., 2009), which is an important therapeutic consideration. The 
exact mechanisms of nabilone metabolism are not known, however it undergoes rapid 
metabolism to several metabolites including isomeric carbinols (Rubin et al., 1977), and 
given the long duration of action relative to its rapid metabolism, it has been postulated that 
some metabolites of nabilone are pharmacologically active.  
4. Clinical evidence 
4.1 Self-medication with cannabis 
Despite the difficulties of obtaining reliable data, epidemiological studies have found that 
people with conditions varying from chronic pain, multiple sclerosis (MS), and spinal cord 
injury sometimes self-medicate with cannabis (Ware et al., 2002). Because cannabis is a 
restricted drug, for which both possession and supply are illegal in most countries, these 
surveys have often tended to come from Canada, where the practice of self-medication with 
cannabis is most openly tolerated (Ogborne et al., 2000a; Ogborne et al., 2000b), although 
some data is available from the US, UK, and continental Europe.  
In Canadian studies of people with chronic pain, up to 38% of the subjects used cannabis 
daily , with 58% of those people using cannabis more than once a day (Ware et al., 2003). 
Consumption of cannabis was between 1 and 5 grams a day, which represents up to 
approximately 65mg THC per day (Lynch et al., 2006). In the UK, 25% of sufferers of chronic 
pain surveyed had self-medicated with cannabis (Ware et al., 2005). Woolridge and 
colleagues (Woolridge et al., 2005) found that among 523 HIV-positive patients, almost 27% 
reported (in an anonymous questionnaire) that they used cannabis to help with HIV 
associated pain, and most users reported that they experienced improvements in muscle 
pain (94%) and neuropathic pain (90%). 
Some surveys have suggested that large numbers of patients with MS might self-medicate 
with cannabis (Clark et al., 2004; Ware et al., 2005). In one survey in the UK, 75 patients with 
MS were questioned, of which 49 experienced chronic pain. Of these patients, 83.7% had 
tried cannabis to help treat their condition, and 75.6% reported that it provided some relief 
for their pain (Chong et al., 2006). In an earlier survey that targeted patients with MS that 
self-medicated with cannabis, some 95% of respondents reported that cannabis improved 
chronic pain to their extremities, spasticity, and some other symptoms such as bladder and 
bowel dysfunction (Consroe et al., 1997).  
The use of cannabis to treat HIV related symptoms was assessed by Woolridge and 
colleagues (Woolridge et al., 2005), who surveyed the use of cannabis in HIV-positive 
individuals attending a large clinic with an anonymous cross-sectional questionnaire. Of 
www.intechopen.com
 
Neuropathic Pain 88
those that responded (n=523) 27% reported that they self-medicated with cannabis. 
Cannabis was reported by the patients to improve appetite (97%), muscle pain (94%), nausea 
(93%), nerve pain (90%), and paresthesia (85%), but also anxiety (93%) and depression 
(86%). However, the survey also found that 47% of the cannabis users reported some degree 
of memory loss.  
People with spinal cord injury are another group where self-medication with cannabis is 
often reported. At the 1998 International Cannabinoid Research Society meeting Consroe 
and colleagues (Consroe et al., 1998) reported the results of a survey of 190 people with 
spinal cord injury who belonged to the Alliance for Cannabis Therapeutics of the US. Of the 
106 valid respondents, 70% used cannabis along with other medications, and 82% reported 
that their symptoms became worse when they stopped using cannabis. Improvements were 
reported for muscle spasms, bladder control, muscle and phantom pains, headache, 
parathesia, and even paralysis. In a more recent survey of patients with spinal cord injury in 
the US (Cardenas et al., 2006), 117 patients were questioned about current and past use of 
treatments. One in seven patients reported having tried an alternative treatment, with 
cannabis being the most frequently cited. Cannabis was reported to reduce chronic pain by 
this group by 6.6 points on an 11 point scale, greater than the degree of relief provided by 
their opioid medications (6.3 points).  
In surveys where medicinal cannabis users were targeted, their reasons for use varied 
considerably, although pain related conditions often appeared high on the list. Schnelle and 
colleagues reported the results of an anonymous survey of medicinal cannabis users in 
Germany, Austria and Switzerland (Schnelle et al., 1999). Out of 128 patients that could be 
included, 12% used medicinal cannabis for depression, 10.8% for MS, 9% HIV-infection, 
6.6% migraine, 6% asthma, 5.4% back pain (and 2.4% disk prolapse), 2.4% spinal cord injury, 
3% glaucoma, 3.6% spasticity, and 3% nausea. Other conditions included hepatitis C, 
sleeping disorders, epilepsy, headache, and alcoholism. In this survey, 72.2% of the patients 
reported that their symptoms were “much improved” by cannabis. In another study, Swift 
and colleagues (Swift et al., 2005) published the results of an Australian survey following 
approval of the trial of medical cannabis by the New South Wales State Government. 
Anonymous questionnaires from 128 participants revealed self-medication with cannabis 
for chronic pain (57%), depression (56%), arthritis (35%), nausea (27%) and weight loss 
(26%). Cannabis was also reported to provide substantial relief for pain, nausea and 
insomnia (Swift et al., 2005). Overall, Australian medical cannabis users reported 
considerable relief from their symptoms.  
Broad survey data on cannabis use sometimes pool recreational and medicinal users, 
however, despite differences between patterns and levels of use These studies can therefore 
tend to record frequency of use rather than amounts and potency, measures that are not 
precisely relevant to people who are self-medicating. Therefore, informal anecdotal or broad 
survey data is an unreliable guide as to the typical amounts of cannabis and equivalent THC 
dosages used by people who are self-medicating.  
4.2 Clinical case reports 
Between surveys and randomized clinical trials are clinical case reports. These are often 
suggestive of a therapeutic effect, but with low N numbers and often lacking placebo 
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controls, are hard to interpret, and sometimes contradict the results of non-clinical 
experiments. For example, cannabis has been reported by some doctors to reduce pendular 
nystagmus (Schon et al., 1999; Dell'Osso, 2000), but careful experimentation with more 
sensitive instruments appears to show that cannabis has little or no effect on the functioning 
of the vestibular system in humans (Spector, 1973). 
Some of the best case studies are controlled experiments, albeit with an N of 1, and include 
controls consisting of placebos or other drugs. For example,  in a study of patient with chronic 
pain from Mediterranean fever, it was found that the patient significantly increased morphine 
administration when during periods in the study when he was given a placebo instead of 50 
mg THC (Holdcroft et al., 1997). In another study, a single patient with spinal cord injury was 
treated with either oral THC (5 mg), codeine (50 mg), or a placebo in a double blind trial 
(Maurer et al., 1990). The study found that THC had a similar analgesic effect to codeine when 
compared with the placebo, and furthermore that THC reduced spasticity. 
Although small clinical case studies and experiments continue to appear in the literature, 
and although they are of enormous value in indicating valuable directions for more 
intensive clinical research, the evidence base for the use of cannabinoid therapeutics is 
rapidly becoming dominated by larger scale clinical trials. For good compilations of clinical 
observation and anecdote, together with the best clinical trial data of the time and expert 
interpretation, three publications all released in 1997 by the British Medical Association 
(BMA) (BMA, 1997), the US National Institutes of Health (NIH) (Bethesda, 1997), and the 
American Medical Association (AMA) (Report of the Council on Scientific Affairs to AMA House 
of Delegates on Medical Marijuana., 1997) are authoritative. Additional compilations of patient 
and doctor testimony can be found in Iversen (Iversen, 2000). 
4.3 Randomized clinical trials 
4.3.1 Acute pain 
Campbell et al. (Campbell et al., 2001) reviewed controlled clinical trials, and found that in two 
trials of acute pain, THC or analogues at tolerable doses were no more effective than codeine, 
despite increased psychoactivity . Similarly, smoked cannabis was shown to be ineffective in 
models of experimental acute pain in healthy volunteers, and actually appeared to increase 
pain sensitivity at higher doses (Hill et al., 1974; Wallace et al., 2007). While this suggests that 
cannabinoids have minimal efficacy in treating acute nociceptive pain, research in to the use of 
cannabinoids as adjuvants to opiates for acute pain continues  (Greenwald et al., 2000; Buggy et 
al., 2003; Naef et al., 2003). At least one clinical study has found that THC interacts with 
morphine to reduce the emotional component of pain (Roberts et al., 2006). Adjuvant therapy 
would be an attractive therapeutic option due to the adverse effects of opioids when 
administered at therapeutic doses. Morphine and other opioids cause a number of unwanted 
and often dose limiting effects, such as constipation, respiratory depression, drowsiness, lack 
of awareness, and even opioid induced hyperalgesia.  
4.3.2 Neuropathic pain 
Ashton and Milligan (Ashton et al., 2008) reviewed clinical trials on cannabinoid treatment 
of neuropathic pain, and found that 15 studies from a total of 18 demonstrated a moderate 
beneficial effect from cannabinoid treatment.  
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Wade et al. (Wade et al., 2003) tested whether cannabis extracts (THC, cannabidiol, or 
Sativex) could treat neurogenic pain and spasm that were intractable to conventional 
treatment. Pain relief from the drugs was significantly greater than from the placebo. 
Notcutt et al. (Notcutt et al., 2004) reported that the same three drugs were effective 
treatments for neuropathic pain, with a side effect profile similar to that for other 
psychoactive drugs for chronic pain. Berman et al. (Berman et al., 2004)  found that Sativex 
and GW-2000-02 (a cannabis extract containing mostly THC; GW Pharmaceuticals) reduced 
pain from brachial plexus avulsion for patients with pain refractory to other analgesics, 
while  Sativex has shown further promise in treating allodynia in neuropathic pain syndromes 
of varying origin (Nurmikko et al., 2007). Pinsger et al. (Pinsger et al., 2006), and Berlach et al. 
(Berlach et al., 2006) have both tested whether nabilone can control chronic pain, and found a 
statistically significant decrease in pain, with side effects generally mild. Ajulemic acid, a 
synthetic analogue of an active metabolite of THC, was found to reduce neuropathic pain in a 
study by Kaarst et al. (Karst et al., 2003). The results of the study were further extended by 
Salim et al. (Salim et al., 2005), who calculated that for a clinically relevant 30% reduction in 
pain, NNT values were 2.14 and 5.29 in two subgroups of patients. 
Clinical trials of cannabinoids in multiple sclerosis induced pain are similarly positive. 
Svendsen et al. (Svendsen et al., 2004) found that pain was reduced by dronabinol in 
patients with multiple sclerosis related central pain. Nabilone was tested in multiple 
sclerosis by Wissel et al. (Wissel et al., 2006)  who found that pain was reduced by nabilone, 
but not placebo. A trial of Sativex for the treatment of patients with multiple sclerosis and 
refractory neuropathic pain by Rog et al. (Rog et al., 2005), found that Sativex relieved pain 
and was mostly well tolerated. Wade et al. (Wade et al., 2006), in a follow up open-label 
study to the earlier placebo-controlled trial (Wade et al., 2004) found that mean pain scores 
were reduced over a 6 week placebo-controlled trial period and then were reduced in the 
open label study to 40-50% of the baseline scores by weeks 10-26. In the UK, the 
“Cannabinoids in Multiple Sclerosis (CAMS)” trial compared cannabis extract (Cannador) 
and dronabinol with placebo (Zajicek et al., 2003). Pain was significantly improved by 
treatment with either cannabinoid preparation over placebo. Following the main study there 
was a follow-up  double-blinded trial for 12 months (Zajicek et al., 2005),  and pain was 
again relieved to a greater degree in cannabinoid groups over the placebo group.  
Two other pain syndromes, HIV-related pain and fibromyalgia deserve special note. 
Smoked cannabis was found to significantly reduce HIV-induced neuropathic pain by 
(Abrams et al., 2007), and fibromyalgia-related pain has now been found to be significantly 
reduced by THC analogues in a number of clinical studies (Schley et al., 2006; Wood et al., 
2007; Skrabek et al., 2008). 
Clinical evidence for the efficacy of cannabinoids in the treatment of neuropathic pain has 
not all been positive, and several trials have reported a lack of efficacy. Two of these trials, 
by Claremont-Gnamien et al. (Clermont-Gnamien et al., 2002) and Attall et al. (Attal et al., 
2004), used oral dronabinol, but lacked placebo-controls. In a well controlled study, another 
report found that nabilone performed poorly compared with dihydrocodeine in treating 
neuropathic pain of varying origins (Frank et al., 2008). Despite the efficacy of Sativex in 
treating painful neuropathies (Nurmikko et al., 2007), a recent study in patients suffering 
painful diabetic neuropathy has been disappointing, with Sativex having no greater effect at 
relieving pain than placebo (Selvarajah et al., 2010). Similarly , Wade et al. (Wade et al., 
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2004) failed to find a beneficial effect on multiple sclerosis induced pain using Sativex. In 
this instance, Iskedjian et al. (Iskedjian et al., 2007) noted that the placebo effect was 
unusually large, and patients had unrestricted access to other analgesics. Arguably if Sativex 
was actually effective in the trial, patients receiving the placebo would initially experience 
more pain, but then take more of the other analgesics, increasing the apparent pain 
reduction in the placebo group. This is feasible, as in one case report, a patient with chronic 
pain increased use of morphine during periods when he was given a placebo instead of 
THC (Holdcroft et al., 1997).  
4.3.3 Secondary outcomes 
Sleep is also an essential aspect of quality of life, and patients with chronic pain often have 
difficulty sleeping. Sleep disturbance is itself disturbing and unpleasant, and lack of sleep 
contributes to fatigue during waking hours. Insomnia is generally treated with central 
nervous system depressants, which have a number of problems with long term use, 
including the development of tolerance and dependence, rebound anxiety and insomnia (as 
well as more severe withdrawal effects), and problems with cognition. Cannabinoids have 
soporific effects, and the possibility that cannabinoids can help improve sleep when given to 
patients with chronic pain has been the subject of clinical trials, generally as a secondary 
outcome measure. In particular, Russo and colleagues (Russo et al., 2007) reviewed the 
effects of either Sativex in nine clinical trials where sleep disturbance, duration and/or 
quality was recorded as a secondary outcome measure. The primary outcome measures of 
these trials were effects on pain, symptoms of multiple sclerosis, and symptoms of arthritis. 
Seven out of nine trials found that sleep was improved in patients receiving Sativex 
compared to patients receiving placebo.  
4.4 Assessing the evidence 
In 1997 the British Medical Association reviewed 8 clinical studies (BMA, 1997) and 
concluded that cannabinoids have a role as adjuvant analgesics for pain conditions 
refractory to standard drugs. Also in 1997, similar conclusions were made in reports by the 
American Medical Association (Report of the Council on Scientific Affairs to AMA House of 
Delegates on Medical Marijuana., 1997) and the US National Institutes of Health  (Bethesda, 
1997). Despite this, it is clear to see that the evidence from clinical trials is not consistent, 
with some but not all trials showing a moderate effect on neuropathic pain from 
cannabinoid treatment.  
The inconsistency of the evidence may be partly due to the inconsistency of the quality of 
the randomized clinical trials. The risk of unblinding of subjects to treatment has been high 
in a number of trials; some subjects had prior exposure to cannabis or even cannabinoid 
drugs in open phases of the trials. Another possible explanation for the inconsistency of 
evidence could be the heterogeneity of pain syndromes and outcome measures across trials. 
Much of the evidence for antinociceptive effects in neuropathic pain comes from studies 
primarily aimed at assessing spasticity in multiple sclerosis, or neuropathic pain of varying 
origin and severity. In conditions with severe neuropathies, cannabinoids at tolerable doses 
may be less efficacious. This is illustrated by the disparity between the positive results of 
Nurmikko et al. (Nurmikko et al., 2007), who report Sativex was efficacious in the treatment 
of neuropathic pain of different origins, and those of Selvarajah et al., (Selvarajah et al., 
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2010), who report no effect of Sativex on painful poly-neuropathy. This issue is discussed in 
a major recent systematic review of drug treatment for neuropathic pain (Finnerup et al., 
2010). In it, Finnerup et al. concluded that cannabinoids have a small effect on central pain 
in multiple sclerosis, mixed neuropathic pain and in peripheral neuropathic pain, but not in 
painful poly-neuropathy.  
A meta-analysis published in 2007 (Iskedjian et al., 2007) reported that cannabinoids are 
useful for neuropathic pain. Iskedjian et al. (Iskedjian et al., 2007) analysed data from 6 
published studies and additional unpublished data from GW Pharmaceuticals. Sativex 
decreased pain by 1.7 +/- 0.7 points (p = 0.018) on an 11-point scale; cannabidiol by 1.5 +/- 
0.7 points (p = 0.044); dronabinol by 1.5 +/- 0.6 points (p = 0.013). Pooling the 3 drugs 
together, pain reduction was 1.6 +/- 0.4 points (p < 0.001) for the cannabinoid group, in 
contrast to 0.8 +/- 0.4 points (p = 0.023) for the placebo. Average baseline scores in the trials 
were around 50-70% of the maximum possible pain, thus a cannabinoid-induced 1.6 point 
reduction on a 11-point scale would be equate to an approximately 24% reduction in pain. 
An important consideration in analysing this clinical data is that many trials have studied 
patients with pain refractory to conventional treatment, and concomitant analgesia is the 
norm, thus some part of the analgesia provided by the cannabinoids may be masked. In 
addition, most trials only tested for pain reduction for a short time; Isdekjian et al. (Iskedjian 
et al., 2007) found that pain reduction was doubled in subjects receiving a cannabis-based 
medicinal extract (CBME) at 6-10 weeks compared with earlier times, an approximate 
halving of baseline pain scores. It was further suggested that the patients in the drug group 
who showed improvement for pain could be “cannabinoid responders” who have greater 
than the average pain relief. 
5. Safety and tolerability   
5.1 Adverse events 
In clinical trials using cannabinoids, adverse side effects are dose dependent, and appear to 
vary in intensity from trial to trial, and between individuals within trials. Possible side 
effects include euphoria, dysphoria, anxiety, depersonalisation, sedation and drowsiness, 
distorted perception, mental clouding, memory impairment, impairment on cognitively 
demanding tasks, fragmentation of thoughts, and even hallucinations. Cannabinoids also 
stimulate appetite, and in some contexts this might possibly be considered an undesired 
effect; though it is an effect that is actively sought when cannabinoids are used to stimulate 
weight gain in patients suffering from wasting after HIV infection or chemotherapy. Acute 
cannabis toxicity can cause psychotic episodes involving delusions and paranoia. With 
respect to motor function, cannabis can cause hypermotility (increased motor activity, 
movement) followed by lethargy, lack of coordination or ataxia, muscle twitches, tremors 
and weakness, and problems speaking (dysarthia). Pregnant women should avoid 
cannabinoids, as this been linked to the impairment of fetal development (Hurd et al., 2005; 
Huizink et al., 2006), even though the evidence for this is inconsistent (Chiriboga, 2003). 
Most clinical trials discussed earlier also contain data on adverse effects. These are mostly 
minor, and virtually all the trials describe the drug as “well tolerated”. The most common 
side effects reported in the trials are drowsiness, ataxia, euphoria and dizziness. At higher 
doses, dissociation and distorted perception are infrequently reported. For example, in the 
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trials carried out by Berman et al. (Berman et al., 2004) and Rog et al. (Rog et al., 2005), 
approximately 25 mg of THC was used, and adverse effects were mild to moderate, and 
usually spontaneously resolved. In both trials the most common side effects were dizziness 
and drowsiness. In the Rog et al. (Rog et al., 2005) trial, 53% of patients experienced at least 
one episode of dizziness, 1 out of 34 patients experienced drowsiness (“somnolence”) and 1 
out of 34 experienced dissociation and ataxia (“feeling drunk”). It is important to note that 
this trial (which is typical) recorded at least one minor adverse event for 88.2% of patients on 
the drug, but to put this in context, the figure is 68.8% for patients taking the placebo.  
As neuropathic pain is a condition requiring long term treatment, it is important to assess 
the adverse effects of any treatment over an appropriate time course. Wade et al. (Wade et 
al., 2006) and Zajicek et al. (Zajicek et al., 2005) both reported on the long term effects of 
THC medication in pain conditions. Wade et al. (Wade et al., 2006) extended a placebo 
controlled acute trial in multiple sclerosis patients, and investigated long term Sativex use in 
an open label trial. They noted that adverse effects were mild in most cases, and the few 
serious events recorded (seizure, gastroenteritis, pneumonia) could not be definitively 
linked to Sativex use, as patients were taking other medications, and multiple sclerosis in 
itself is a risk factor for some of the recorded events. Similarly, Zajicek et al. (Zajicek et al., 
2005) extended a placebo controlled trial of dronabinol and cannabis extract (Cannador) in 
multiple sclerosis patients, and recorded adverse events for a year. Unlike the Wade et al. 
follow up, the design of the study allowed comparison of cannabinoid treatment with an 
inactive placebo. While minor and serious adverse events were reported in the cannabinoid 
groups, incidence rates were comparable with placebo (Zajicek et al., 2005). Overall both 
studies conclude that in general, adverse effects were mild, and long term cannabinoid 
treatment was well tolerated. 
5.2 Tolerance and dependence 
In studies dealing with self medication with cannabis, it is difficult to accurately calculate 
equivalent doses of THC, as frequency, amount, and potency of smoked cannabis leaf are 
highly variable between users. A recent study with 30 subjects in Canada found that people 
who used cannabis to treat themselves for chronic pain used between 1 and 5 grams of 
cannabis a day, with an average of 2.5 grams/day (Lynch et al., 2006). The THC content in 
cannabis cigarettes usually ranges between 1.5 to 3.7%, so smoking 2.5g per day translates 
into a daily intake of 38 to 93 mg of THC. As only 10 to 25% of the THC in smoked cannabis 
leaf will be absorbed into the bloodstream (Adams et al., 1996), this equates to 3.8 to 23 mg 
of THC per day. The other systematic source of data on amounts of THC that will be sought 
by people seeking relief from chronic pain comes from clinical trials where the patients are 
allowed to “self-titrate”. This is where the patient has ad libitum access to the drug (within an 
upper limit), and takes the drug as required. In this way, the patient finds a balance between 
the desired and undesired effects to fit their individual needs. In these self-titrating trials, 25 
mg of THC was a typical amount of the drug that was taken during a day. Therefore, there 
appears to be a reasonable correlation between the amounts of THC that people seek from 
self-medication with cannabis, and from purified extracts in clinical trials. 
People who self-titrate, or self-medicate for THC may raise the dose that they seek over 
time, because they can become tolerant to the analgesic effects of THC (Association, 1997; 
Lichtman et al., 2005), and thus seek higher amounts to relieve their pain. At the same time, 
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tolerance also occurs to adverse effects, such as drowsiness and sedation. With respect to 
euphoria and minor adverse effects, moderate and heavy users of cannabis do develop 
tolerance (i.e., a decreased response to the drug) (Lichtman et al., 2005). In one study, heavy 
users smoked an average 5.7 grams of cannabis a day, and showed a progressive decline in 
ratings of intoxication (Babor et al., 1975).  
Cannabis dependence is a recognised syndrome under DSM-IV criteria, and has been the 
subject of a number of epidemiological studies (e.g., (Fergusson et al., 2003; Boden et al., 2006)). 
The official advice seems to indicate that cannabis dependence is not prevalent. The UM 
MRHA 2007 report on Sativex states that only 1% of cannabis users develop dependence on 
the drug. The prescription data sheets for Cesamet and Marinol state that in clinical trials of 
these formulations in patient populations, patients experienced no withdrawal symptoms, 
despite a 5 month trial in the case of Marinol. Both data sheets, however, point to an abstinence 
syndrome in healthy volunteers after the cessation of large daily doses of THC (200 mg), 
administered over 12 – 16 days. Withdrawal symptoms included some distress, sleep 
disturbances and autonomic hyperactivity, lasting for 48 hours after drug cessation. 
6. Future drug development 
One of the limiting factors for the widespread clinical use of cannabinoids is adverse 
psychoactivity. As discussed earlier, this is caused exclusively by activation of CB1 receptors 
in the central nervous system. One important aim of research into cannabinoid receptors as 
therapeutic targets is to obtain ligands with clinically useful effects, but without (or at least 
minimizing) the psychoactive unwanted effects. The chronic pain relieving properties are 
thought to be mediated via activation of not only central CB1 receptors, but also spinal and 
peripheral CB1 and CB2 receptors. Recent cannabinoid drug development has attempted to 
exploit the apparent redundancy of the cannabinoid system in pain, developing ligands 
selective for non-psychoactive or peripheral cannabinoid receptors. 
Because of the distinct distributions and physiological functions of CB1 and CB2, there has 
been intensive research into developing ligands specific for a particular receptor, 
particularly the “non-psychoactive” CB2 receptor. HU-308 is a highly selective bicyclic CB2-
agonist, related to WIN55,212-2 and JWH-133, with a 440-fold selectivity for CB2 over CB1  
(Hanus et al., 1999). At the time of writing, HU-308 has restricted availability, and is being 
intensively studied by several research groups for its potential therapeutic potential. 
Another highly selective CB2 agonist, GW405833, has been synthesised (Valenzano et al., 
2005), and is also a derivative of WIN55,212-2. Crucially, although this compound has only 
80-fold selectivity for the CB2 receptor over the CB1 receptor in rats, it has a 1200-fold 
selectivity for CB2 over CB1 in humans. GW405833 is a partial agonist at CB2 (Kearn et al., 
1999). Preclinical research into these compounds has been promising, although clinical 
translation has been less so. GlaxoSmithKline tested GW842166, a potent CB2 agonist, and 
found it to be highly efficacious in an animal model of inflammatory pain. In the clinic, 
however, this compound had no effect on acute dental pain compared to placebo in a 
paradigm where 800 mg ibuprofen was efficacious (Ostenfeld et al., 2011). This said, it must 
be questioned why a condition of acute pain was chosen for clinical testing in this instance, 
as cannabinoids have typically been more efficacious in chronic pain conditions. 
Alternatively, the selective targeting of peripheral cannabinoid receptors would also 
circumvent unfavourable psychoactivity. AstraZeneca have been conducting preclinical and 
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clinical trials with several peripherally restricted cannabinoid agonists with mixed results. 
Preclinical trials with AZ11713908 (Yu et al., 2010) and AZD1940 (Groblewski et al., 2010b) 
indicated antinociceptive efficacy in animal models of inflammatory and neuropathic pain, 
and minimal CNS penetration. In clinical trials, however, AZD1940 reportedly had no effect 
on acute dental pain, or chronic back pain (Groblewski et al., 2010a). 
7. Conclusions 
Cannabis is widely used by people suffering from neuropathic pain, with many users 
reporting pain relieving effects. In more quantitative analyses, cannabinoids appear to have 
a moderate efficacy in the treatment of chronic and neuropathic pain of varying origin, with 
adverse effects and dependence risk minimal when compared with traditional analgesics, 
especially opioids. Despite a lack of efficacy in every neuropathic condition, and dose 
limiting adverse effects of these compounds, there appears to be a large body of evidence 
supporting a continued role of cannabinoids as analgesics in some instances, especially in 
patients refractory to current treatments. The development of more efficacious and well 
tolerated drugs in this class will enable a more widespread application these 
pharmacotherapeutics in neuropathic pain. 
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